Loss of hepatic SMLR1 causes hepatosteatosis and protects against atherosclerosis due to decreased hepatic VLDL secretion - Nantes Université
Article Dans Une Revue Hepatology Année : 2022

Loss of hepatic SMLR1 causes hepatosteatosis and protects against atherosclerosis due to decreased hepatic VLDL secretion

Willemien van Zwol
Umesh Tharehalli
  • Fonction : Auteur
Simon M de Neck
  • Fonction : Auteur
Marceline M Fuh
  • Fonction : Auteur
Jeroen Kuipers
  • Fonction : Auteur
Sujith Rajan
  • Fonction : Auteur
Ludger Scheja
  • Fonction : Auteur
Joerg Heeren
  • Fonction : Auteur
Philip Zimmerman
  • Fonction : Auteur
Bart van de Sluis
  • Fonction : Auteur
Jan Albert Kuivenhoven
  • Fonction : Auteur
  • PersonId : 1433902

Résumé

Hypobetalipoproteinemia is characterized by LDL-cholesterol and apolipoprotein B (apoB) plasma levels below the fifth percentile for age and sex. Familial hypobetalipoproteinemia (FHBL) is mostly caused by premature termination codons in the APOB gene, a condition associated with fatty liver and steatohepatitis. Nevertheless, many families with a FHBL phenotype carry APOB missense variants of uncertain significance (VUS). We here aimed to develop a proof-of-principle experiment to assess the pathogenicity of VUS using the genome editing of human liver cells. We identified a novel heterozygous APOB-VUS (p.Leu351Arg), in a FHBL family. We generated APOB knock-out (KO) and APOB-p.Leu351Arg knock-in Huh7 cells using CRISPR-Cas9 technology and studied the APOB expression, synthesis and secretion by digital droplet PCR and ELISA quantification. The APOB expression was decreased by 70% in the heterozygous APOB-KO cells and almost abolished in the homozygous-KO cells, with a consistent decrease in apoB production and secretion. The APOB-p.Leu351Arg homozygous cells presented with a 40% decreased APOB expression and undetectable apoB levels in cellular extracts and supernatant. Thus, the p.Leu351Arg affected the apoB secretion, which led us to classify this new variant as likely pathogenic and to set up a hepatic follow-up in this family. Therefore, the functional assessment of APOB-missense variants, using gene-editing technologies, will lead to improvements in the molecular diagnosis of FHBL and the personalized follow-up of these patients.
Fichier principal
Vignette du fichier
loss_of_hepatic_smlr1_causes_hepatosteatosis.pdf (1.92 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Licence

Dates et versions

hal-04060059 , version 1 (29-10-2024)

Licence

Identifiants

Citer

Willemien van Zwol, Antoine Antoine Rimbert, Justina C Wolters, Marieke Smit, Vincent W Bloks, et al.. Loss of hepatic SMLR1 causes hepatosteatosis and protects against atherosclerosis due to decreased hepatic VLDL secretion. Hepatology, 2022, 23 (8), pp.n/a-n/a. ⟨10.1002/hep.32709⟩. ⟨hal-04060059⟩
28 Consultations
7 Téléchargements

Altmetric

Partager

More